Novo Nordisk Opens Wegovy to Telehealth, Sending Hims & Hers Shares Soaring
Imagine dialing up your doctor for a weight-loss prescription as easily as ordering takeout. That’s essentially the new reality for Wegovy, Novo Nordisk’s blockbuster obesity drug, which is now being offered through telehealth platforms. In late April 2025, Novo Nordisk announced it would partner with telemedicine companies to sell Wegovy directly to consumers . This news set the stock market abuzz, and shares of Hims & Hers – a telehealth company – shot up dramatically, rocketing as much as 40% intraday and eventually closing the day roughly 18% higher. What’s going on here? Let’s unpack the details of this landmark deal, why it’s a game-changer for weight-loss drugs, and how it fueled a surge in Hims & Hers’ stock. Background on Wegovy and Novo Nordisk Wegovy is the brand name for semaglutide in a high-dose injection form, developed by Danish pharma giant Novo Nordisk . It’s a GLP-1 receptor agonist originally used to treat diabetes (as Ozempic), but repurposed for ...
.jpg)